Literature DB >> 4324569

Corticosteroid and growth hormone secretion in patients treated with L-dopa.

K von Werder, G R van Loon, F Yatsu, P H Forsham.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 4324569     DOI： 10.1007/bf01484684

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


× No keyword cloud information.
  9 in total

1.  THE ADRENOCORTICAL RESPONSE TO INSULIN-INDUCED HYPOGLYCAEMIA.

Authors:  J LANDON; V WYNN; V H JAMES
Journal:  J Endocrinol       Date:  1963-11       Impact factor: 4.286

2.  THE ROLE OF CENTRAL NERVOUS ACTIVATING AND INHIBITORY STRUCTURES IN THE CONTROL OF PITUITARY-ADRENOCORTICAL FUNCTION. EFFECTS OF INTRACEREBRAL CHOLINERGIC AND ADRENERGIC STIMULATION.

Authors:  E ENDROECZI; G SCHREIBERG; K LISSAK
Journal:  Acta Physiol Acad Sci Hung       Date:  1963

3.  An immunochemical assay of total extractable insulin in man.

Authors:  G M GRODSKY; P H FORSHAM
Journal:  J Clin Invest       Date:  1960-07       Impact factor: 14.808

4.  Modification of the Reddy-Jenkins-Thorn method for the estimation of 17-hydroxycorticoids in urine.

Authors:  W J REDDY
Journal:  Metabolism       Date:  1954-11       Impact factor: 8.694

5.  Application of the Feulgen reaction to smears in exfoliative cytology.

Authors:  E S MEEK
Journal:  J Clin Pathol       Date:  1962-07       Impact factor: 3.411

6.  The determination of urinary steroids. I. The preparation of pigment-free extracts and a simplified procedure for the estimation of total 17-ketosteroids.

Authors:  I J DREKTER; A HEISLER; G R SCISM; S STERN; S PEARSON; T H McGAVACK
Journal:  J Clin Endocrinol Metab       Date:  1952-01       Impact factor: 5.958

7.  Effects of L-dopa in Parkinson's disease.

Authors:  R B Godwin-Austen; E B Tomlinson; C C Frears; H W Kok
Journal:  Lancet       Date:  1969-07-26       Impact factor: 79.321

8.  Aromatic amino acids and modification of parkinsonism.

Authors:  G C Cotzias; M H Van Woert; L M Schiffer
Journal:  N Engl J Med       Date:  1967-02-16       Impact factor: 91.245

9.  Adrenergic receptor control mechanism for growth hormone secretion.

Authors:  W G Blackard; S A Heidingsfelder
Journal:  J Clin Invest       Date:  1968-06       Impact factor: 14.808
  9 in total
  5 in total

1.  The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

Authors:  W Birkmayer; P Riederer; M B Youdim; W Linauer
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

2.  Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease before and during therapy.

Authors:  H P Vogel; R Ketsche
Journal:  J Neurol       Date:  1986-06       Impact factor: 4.849

Review 3.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

Review 4.  Antiparkinsonian drugs: pharmacological and therapeutic aspects.

Authors:  D B Calne; J L Reid
Journal:  Drugs       Date:  1972       Impact factor: 9.546

5.  Plasma DOPA levels and growth hormone response to levodopa in parkinsomism.

Authors:  A Galea-Debono; P Jenner; C D Marsden; J D Parkes; D Tarsy; J Walters
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-02       Impact factor: 10.154
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.